Literature DB >> 12239137

The World Health Organization (WHO) classification of the myeloid neoplasms.

James W Vardiman1, Nancy Lee Harris, Richard D Brunning.   

Abstract

A World Health Organization (WHO) classification of hematopoietic and lymphoid neoplasms has recently been published. This classification was developed through the collaborative efforts of the Society for Hematopathology, the European Association of Hematopathologists, and more than 100 clinical hematologists and scientists who are internationally recognized for their expertise in hematopoietic neoplasms. For the lymphoid neoplasms, this classification provides a refinement of the entities described in the Revised European-American Lymphoma (REAL) Classification-a system that is now used worldwide. To date, however, there has been no published explanation or rationale given for the WHO classification of the myeloid neoplasms. The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.

Entities:  

Mesh:

Year:  2002        PMID: 12239137     DOI: 10.1182/blood-2002-04-1199

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  454 in total

1.  Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era.

Authors:  Haiyan He; Yang Shen; Yongmei Zhu; Saijuan Chen
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

2.  Telomere length in myelodysplastic syndromes.

Authors:  Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List
Journal:  Leuk Lymphoma       Date:  2011-06-03

Review 3.  Ribosome defects in disorders of erythropoiesis.

Authors:  Anupama Narla; Slater N Hurst; Benjamin L Ebert
Journal:  Int J Hematol       Date:  2011-02-01       Impact factor: 2.490

4.  Assumption weighting for incorporating heterogeneity into meta-analysis of genomic data.

Authors:  Yihan Li; Debashis Ghosh
Journal:  Bioinformatics       Date:  2012-01-27       Impact factor: 6.937

5.  Prognosis in myelodysplastic syndromes: are the new classifications useful?

Authors:  Naomi Galili; Azra Raza
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

6.  Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.

Authors:  Brunangelo Falini; Maria Paola Martelli; Stefano A Pileri; Cristina Mecucci
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

7.  Splenic and Portal Vein Thrombosis With Concurrent Splenic Infarction: A Rare Manifestation of Essential Thrombocythemia.

Authors:  Manisha Gulia; Neha Sharma; Yajur Arya; Arshi Syal; Monica Gupta
Journal:  Cureus       Date:  2021-06-20

8.  FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

Authors:  Fábio Morato de Oliveira; Carlos Eduardo Miguel; Antônio Roberto Lucena-Araujo; Ana Silvia Gouvêa de Lima; Roberto Passetto Falcão; Eduardo Magalhães Rego
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

9.  Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.

Authors:  Peter McLaughlin; Elihu Estey; Armand Glassman; Jorge Romaguera; Felipe Samaniego; Ana Ayala; Kimberly Hayes; Anne Marie Maddox; H Alejandro Preti; Fredrick B Hagemeister
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

10.  Survival differences in childhood and young adult acute myeloid leukemia: A cross-national study using US and England data.

Authors:  Sherlly Xie; Md Jobayer Hossain
Journal:  Cancer Epidemiol       Date:  2018-03-16       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.